The Mount Sinai NeuroAIDS program is involved in the following research efforts:
- The Manhattan HIV Brain Bank (MHBB). The purpose of the MHBB is to study the neurologic, neuropsychologic, psychiatric, and neuropathologic manifestations of HIV infection. The MHBB is a longitudinal, observational study that follows a group of HIV-infected individuals who have agreed to be fluid and organ donors for the purposes of AIDS research.
- The CNS HIV Antiretroviral Therapy Effects Research (CHARTER). The CHARTER study seeks to determine how neurologic complications of HIV are affected by different antiretroviral therapies. Participants receive comprehensive neuromedical, neurocognitive, and laboratory examinations. CHARTER is conducted at six sites nationally, including Mount Sinai.
- The experience of chronic pain: A focus group approach. This study seeks to explore how patients with chronic pain, including HIV-associated neuropathy, experience their symptoms, with the goal of improving communication between patients and providers.
- A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of pregabalin versus placebo in the treatment of neuropathic pain associated with HIV neuropathy (pregabalin A9451066) and an open-label, extension safety trial of pregabalin in subjects with neuropathic pain associated with HIV neuropathy (pregabalin A0081251). These studies investigate whether pregabalin is an effective treatment for painful HIV-associated neuropathy.
- HIV neurocognitive disorders: A randomized clinical trial of CNS-targeted HAART. This study will seek to determine if antiretroviral therapy with greater CNS penetrance improves HIV-associated neurocognitive disorder.
- A double-blind, placebo-controlled study of intravenous immunoglobulin for HIV-associated myelopathy. HIV-associated myelopathy is a debilitating disorder of the spinal cord. There are currently no therapies proven effective for HIV-associated myelopathy. This study will seek to determine whether intravenous immunoglobulin improves HIV-associated myelopathy.
David M. Simpson, MD
Director of NeuroAIDS Program
Jessica Robinson-Papp, MD